CAR-T Cell Product Development Guidance Covers Previous Recipients, ‘Bridging Therapy’

Testing of autologous therapy in clinical trial patients who previously received CAR-T cells requires special consideration in initial material testing and study design, US FDA says in a draft guidance that also addresses potential need for bridging therapy in the event of a manufacturing delay or failure.